Spread times of hepatitis C virus estimated by the molecular clock differ among Japan, the United States and Egypt in reflection of their distinct socioeconomic backgrounds

Intervirology

Volumn 49, Issue 1-2, 2006, Pages 28-36

  Mizokami, Masashi ^a   Tanaka, Yasuhito ^a   Miyakawa, Yuzo ^b  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b Miyakawa Memorial Research Foundation   (Japan)

Author keywords

Evolution; Hepatitis C virus; Intravenous drugs; Molecular clock; Schistosomiasis; Transfusion

Indexed keywords

ANTIVIRUS AGENT; HEPATITIS C ANTIBODY; INTERFERON;

ANAMNESIS; BLOOD TRANSFUSION; CONFERENCE PAPER; DISEASE ASSOCIATION; DISEASE COURSE; EGYPT; EPIDEMIC; GENOTYPE; HEMOLYSIS; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; JAPAN; LIVER CELL CARCINOMA; MICROBIAL POPULATION DYNAMICS; MOLECULAR CLOCK; NONHUMAN; POPULATION SIZE; PREDICTION; PRIORITY JOURNAL; SCHISTOSOMA JAPONICUM; SCHISTOSOMIASIS; SIMULATION; SOCIAL STATUS; UNITED STATES; VIROGENESIS; VIRUS MUTATION; VIRUS TRANSMISSION;

BASE SEQUENCE; CARCINOMA, HEPATOCELLULAR; EGYPT; EPIDEMIOLOGY, MOLECULAR; FORECASTING; HEPACIVIRUS; HEPATITIS C; HUMANS; JAPAN; LIVER NEOPLASMS; MOLECULAR SEQUENCE DATA; PHYLOGENY; RNA, VIRAL; SEQUENCE ALIGNMENT; SOCIOECONOMIC FACTORS; TIME FACTORS; UNITED STATES; VIRAL ENVELOPE PROTEINS; VIRAL NONSTRUCTURAL PROTEINS;

HEPATITIS C VIRUS;

EID: 24944433096     PISSN: 03005526     EISSN: None     Source Type: Journal    
DOI: 10.1159/000087260     Document Type: Conference Paper

References (41)

1. Cohen J: The scientific challenge of hepatitis C. Science 1999;285:26-30.
2. Lee WM: Hepatitis B virus infection. N Engl J Med 1997;337:1733-1745.
3. Blumberg BS: Polymorphisms of the serum proteins and the development of iso-precipitins in transfused patients. Bull NY Acad Med 1964;40:377-386.
4. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M: Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989;244:359-362.
5. Kuo G, Choo QL, Alter HJ, Gitnick GL, Redeker AG, Purcell RH, Miyamura T, Dienstag JL, Alter MJ, Stevens CE, et al: An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 1989;244:362-364.
6. Kiyosawa K, Sodeyama T, Tanaka E, Gibo Y, Yoshizawa K, Nakano Y, Furuta S, Akahane Y, Nishioka K, Purcell RH, Alter HJ: Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: Analysis by detection of antibody to hepatitis C virus. Hepatology 1990;12:671-675.
7. Tong MJ, el-Farra NS, Reikes AR, Co RL: Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995;332:1463-1466.
8. Hamada H, Yatsuhashi H, Yano K, Daikoku M, Arisawa K, Inoue O, Koga M, Nakata K, Eguchi K, Yano M: Impact of aging on the development of hepatocellular carcinoma in patients with posttransfusion chronic hepatitis C. Cancer 2002;95:331-339.
9. Zuckerkandel E, Pauling L: Evolutionary divergence and convergence in proteins; in Bivson V, Vogel HJ (eds): Evolving Genes and Proteins. New York, Academic Press, 1962, pp 97-166.
10. Margoliash E: Primary structure and evolution of cytochrome C. Proc Natl Acad Sci USA 1963;50:672-679.
11. Tanaka Y, Hanada K, Mizokami M, Yeo AE, Shih JW, Gojobori T, Alter HJ: A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades. Proc Natl Acad Sci USA 2002;99:15584-15589.
12. Tanaka Y, Agha S, Saudy N, Kurbanov F, Orito E, Kato T, Abo-Zeid M, Khalaf M, Miyakawa Y, Mizokami M: Exponential spread of hepatitis C virus genotype 4a in Egypt. J Mol Evol 2004;58:191-195.
13. Pybus OG, Charleston MA, Gupta S, Rambaut A, Holmes EC, Harvey PH: The epidemic behavior of the hepatitis C virus. Science 2001;292:2323-2325.
14. Kimura M: Evolutionary rate at the molecular level. Nature 1968;217:624-626.
15. Alter HJ, Purcell RH, Shih JW, Melpolder JC, Houghton M, Choo QL, Kuo G: Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med 1989;321:1494-1500.
16. Conry-Cantilena C, VanRaden M, Gibble J, Melpolder J, Shakil AO, Viladomiu L, Cheung L, DiBisceglie A, Hoofnagle J, Shih JW, et al: Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med 1996;334:1691-1696.
17. Ogata N, Alter HJ, Miller RH, Purcell RH: Nucleotide sequence and mutation rate of the H strain of hepatitis C virus. Proc Natl Acad Sci USA 1991;88:3392-3396.
18. Ina Y, Mizokami M, Ohba K, Gojobori T: Reduction of synonymous substitutions in the core protein gene of hepatitis C virus. J Mol Evol 1994;38:50-56.
19. Okamoto H, Kojima M, Okada S, Yoshizawa H. Iizuka H, Tanaka T, Muchmore EE, Peterson DA, Ito Y, Mishiro S: Genetic drift of hepatitis C virus during an 8.2-year infection in a chimpanzee: Variability and stability. Virology 1992;190:894-899.
20. Stumpf MP, Pybus OG: Genetic diversity and models of viral evolution for the hepatitis C virus. FEMS Microbiol Lett 2002;214:143-152.
21. Pybus OG, Rambaut A: GENIE: Estimating demographic history from molecular phylogenies. Bioinformatics 2002;18:1404-1405.
22. Lemey P, Pybus OG, Wang B, Saksena NK, Salemi M, Vandamme AM: Tracing the origin and history of the HIV-2 epidemic. Proc Natl Acad Sci USA 2003;100:6588-6592.
23. Yoshizawa H: Hepatocellular carcinoma associated with hepatitis C virus infection in Japan: Projection to other countries in the foreseeable future. Oncology 2002;62:S8-S17.
24. Tanaka J, Kumagai J, Katayama K, Komiya Y, Mizui M, Yamanaka R, Suzuki K, Miyakawa Y, Yoshizawa H: Sex- and age-specific carriers of hepatitis B and C viruses in Japan estimated by the prevalence in the 3,485,648 first-time blood donors during 1995-2000. Intervirology 2004;47:32-40.
25. El-Serag HB: Hepatocellular carcinoma and hepatitis C in the United States. Hepatology 2002;36:S74-S83.
26. Nair S, Shiv Kumar K, Thuluvath PJ, Shivakumar KS, Shiva Kumar K: Mortality from hepatocellular and biliary cancers: Changing epidemiological trends. Am J Gastroenterol 2002;97:167-171.
27. Ikeda K, Saitoh S, Arase Y, Chayama K, Suzuki Y, Kobayashi M, Tsubota A, Nakamura I, Murashima N, Kumada H, Kawanishi M: Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology 1999;29:1124-1130.
28. Yabuuchi I, Imai Y, Kawata S, Tamura S, Noda S, Inada M, Maeda Y, Shirai Y, Fukuzaki T, Kaji I, Ishikawa H, Matsuda Y, Nishikawa M, Seki K, Matsuzawa Y: Long-term responders without eradication of hepatitis C virus after interferon therapy: Characterization of clinical profiles and incidence of hepatocellular carcinoma. Liver 2000;20:290-295.
29. Sodeyama T, Kiyosawa K, Urushihara A, Matsumoto A, Tanaka E, Furuta S, Akahane Y: Detection of hepatitis C virus markers and hepatitis C virus genomic-RNA after needle-stick accidents. Arch Intern Med 1993;153:1565-1572.
30. Takagi H, Uehara M, Kakizaki S, Takahashi H, Takezawa J, Kabeya K, Satoh K, Kojima A, Saito S, Matsumoto T, Hashimoto Y, Abe T, Yamada T, Konaka K, Shimoda R, Takayama H, Takehara K, Nagamine T, Mori M: Accidental transmission of HCV and treatment with interferon. J Gastroenterol Hepatol 1998;13:238-243.
31. Terrault NA: Sexual activity as a risk factor for hepatitis C. Hepatology 2002;36:S99-S105.
32. van den Hoek JA, van Haastrecht HJ, Goudsmit J, de Wolf F, Coutinho RA: Prevalence, incidence, and risk factors of hepatitis C virus infection among drug users in Amsterdam. J Infect Dis 1990;162:823-826.
33. Galeazzi B, Tufano A, Barbierato E, Bortolotti F: Hepatitis C virus infection in Italian intravenous drug users: Epidemiological and clinical aspects. Liver 1995;15:209-212.
34. Iida F, Iida R, Kamijo H, Takaso K, Miyazaki Y, Funabashi W, Tsuchiya K, Matsumoto Y: Chronic Japanese schistosomiasis and hepatocellular carcinoma: Ten years of follow-up in Yamanashi Prefecture, Japan. Bull World Health Organ 1999;77:573-581.
35. De Vos Irvine H, Goldberg D, Hole DJ, McMenamin J: Trends in primary liver cancer. Lancet 1998;351:215-216.
36. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ: The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med 1996;334:1685-1690.
37. Frank C, Mohamed MK, Strickland GT, Lavanchy D, Arthur RR, Magder LS, El Khoby T, Abdel-Wahab Y, Aly Ohn ES, Anwar W, Sallam I: The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 2000;355:887-891.
38. McOmish F, Yap PL, Dow BC, Follett EA, Seed C, Keller AJ, Cobain TJ, Krusius T, Kolho E, Naukkarinen R, et al: Geographical distribution of hepatitis C virus genotypes in blood donors: An international collaborative survey. J Clin Microbiol 1994;32:884-892.
39. Pybus OG, Drummond AJ, Nakano T, Robertson BH, Rambaut A: The epidemiology and iatrogenic transmission of hepatitis C virus in Egypt: A Bayesian coalescent approach. Mol Biol Evol 2003;20:381-387.
40. Angelico M, Renganathan E, Gandin C, Fathy M, Profili MC, Refai W, De Santis A, Nagi A, Amin G, Capocaccia L, Callea F, Rapicetta M, Badr G, Rocchi G: Chronic liver disease in the Alexandria governorate, Egypt: Contribution of schistosomiasis and hepatitis virus infections. J Hepatol 1997;26:236-243.
41. Tanaka Y, Hanada K, Orito E, Akahane Y, Chayama K, Yoshizawa H, Sata M, Ohta N, Miyakawa Y, Gojobori T, Mizokami M: Molecular evolutionary analyses implicate injection treatment for schistosomiasis in the initial hepatitis C endemic of Japan. J Hepatol 2005;42:47-53.